Extensions of the mTPI and TEQR designs to include non-monotone efficacy in addition to toxicity for optimal dose determination for early phase immunotherapy oncology trials.
published in: Contemporary clinical trials communications
date of publication: 2018-01-31
main subject: immunotherapy
Cites articles 19
- 2013-09-04
Date
Title
Article - wd:Q55123242